Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Novo Nordisk A/S ADR (NY: NVO )

128.05 +1.32 (+1.04%)
Official Closing Price Updated: 7:00 PM EDT, Jul 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,093,985
Open 128.01
Bid (Size) 126.19 (1)
Ask (Size) 128.05 (3)
Prev. Close 126.73
Today's Range 127.38 - 129.53
52wk Range 78.19 - 148.15
Shares Outstanding N/A
Dividend Yield 1.38%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Overlooked Stocks Poised for a Breakout Very Soon
Discover three overlooked breakout stocks with solid growth prospects, perfect for enhancing your investment portfolio. 
Via InvestorPlace
What Will Be the Best Weight Loss Drug Stock of 2030: Eli Lilly, or Novo Nordisk?
There's reason to believe that one of these two players will eventually win. 
Via The Motley Fool

Performance

YTD
+25.40%
+25.40%
1 Month
-11.94%
-11.94%
3 Month
+0.92%
+0.92%
6 Month
+17.46%
+17.46%
1 Year
+58.97%
+58.97%

More News

Read More
Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?
Via The Motley Fool
Attention, Growth Investors: This Biotech Stock Is Crushing Nvidia.
Via The Motley Fool
This Could Send Ozempic's Sales Potential to a Whole Other Level
Via The Motley Fool
Novo Nordisk Unusual Options Activity For July 26
Via Benzinga
Novo Nordisk's Options Frenzy: What You Need to Know
Via Benzinga
Novo Nordisk's Next-Gen Diabetes Candidate Could Challenge Ozempic -- Is the Stock a Buy?
Via The Motley Fool
Stock Market Diverges, With Tesla, Google, ServiceNow, GE In Focus: Weekly Review
Via Investor's Business Daily
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
Via The Motley Fool
Novo Nordisk Shares Decline Amid Competitive Pressure
Via Benzinga
Viking Therapeutics Stock Surges As Company Advances Weight Loss Drug To Late-Stage Trial: What Investors Need To Know
Via Benzinga
Viking Therapeutics Unveils Monthly Weight-Loss Shot, And Rocks Eli Lilly, Novo Nordisk
Via Investor's Business Daily
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
Via InvestorPlace
Beware, Wegovy -- Pfizer Is Working on a Competitor
Via The Motley Fool
3 Fabulous Growth Stocks to Buy and Hold Forever
Via InvestorPlace
UK's NHS Prescribes Weight-Loss Drug Wegovy Less Than Expected Due To Service Shortages
Via Benzinga
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
Via Benzinga
3 Stocks to Buy if There Is No Interest Rate Cut This Year
Via InvestorPlace
Topics Economy
Exposures Interest Rates
Insulin Device Maker Embecta Weighs Sale After 70% Share Decline Following Becton Dickinson Spin-Off
Via Benzinga
Britain's Drug Regulator Approves Novo Nordisk's Weight Loss Drug Wegovy To Cut Heart Disease Risk In Obese Patients
Via Benzinga
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
Via The Motley Fool
Why Hims & Hers Heath Shares Are Surging Today
Via Benzinga
Biden's Exit From Presidential Race 'Yet Another Curveball For Equity Investors': Analysts
Via Benzinga
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.